SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AutoImmune-AIMM
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dr. John M. de Castro who wrote (187)8/4/1997 3:52:00 PM
From: Biomaven   of 298
 
John,

The release stated:

"In continuing evaluation of data from the recently completed Phase III trial of Myloral(R) for multiple sclerosis, the Company reported that encouraging preliminary results from magnetic resonance imaging have been found for one of the four subsets of patients studied. Further analysis of this information is ongoing."

Assume for a moment that the MRI showed improvements in this one subgroup that did not occur in any of the placebo groups. Might not the FDA be open to an approval for that subgroup based solely on the MRI results, given that the reason for the non-significance was the large placebo effect?

I'm looking at the stock because it's now trading for its cash value, although I suppose they will eat through that in a year or two if they have no positve results.

By the way, just how do you "do everything in your power to reduce the placebo effect?" Remind the patients weekly that they may be taking a placebo? :)

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News